Long-term holders' patience has not been rewarded with these two stocks.
The deal builds on leadership positions in Allergan's core therapeutic areas.
The portfolio still loves the stock, but now is the time to take profits.
ValueAct Capital has a history of investing at the right time of a down cycle.
Support has appeared around $95 recently, but that may give way.
This small-cap is trading below net cash and is rapidly improving its fundamentals.
Do earnings and lower guidance no longer matter to investors?
Metals and minerals had the highest operating margin in a decade.
Is the electric-car maker a money pit -- or the next big thing?
The shocking truth of how the latest round of stimulus under Abenomics is being spent.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.